Clinical trial NCT05402345: A Study of GlcNAc on Tear Production in NGLY1-CDDG
Official title: A Phase II Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Effect Of GlcNAc On Tear Production In Individuals With NGLY1-CDDG
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: NGLY1 Deficiency
Lead sponsor: Icahn School of Medicine at Mount Sinai
Sponsor class: OTHER
Collaborators: name: Children's Hospital of Philadelphia
name: Seattle Children's Hospital
First posted: 2022-06-02
Enrollment: 18
Sex: ALL
Minimum age (years): 1
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In patients with NGLY1-CDDG, the disorder can lead to eye damage due to not being able to produce enough tears. This study is being done to see if the dietary supplement, GlcNAc, improves tear production in patients with NGLY1-CDDG.

Detailed description: This study is a multicenter randomized, double-blind, placebo-controlled trial of GlcNAc supplementation for improvement of tear production in NGLY1-CDDG. Clinical history and screening data will be reviewed to determine subject eligibility. If a subject is already on GlcNAc, a washout period of 1 month will be required prior to consent and randomization. Interested subjects who have a molecularly confirmed diagnosis of NGLY1-CDDG will be consented. Baseline data will be collected prior to randomization at treatment initiation. Subjects will then be randomized to placebo or GlcNAc. They will be administered weight-dependent doses of GlcNAc or an equivalent volume of placebo enterally for 6 weeks, followed by open label weight-dependent doses of GlcNAc for 6 weeks. A visit for evaluation and collection of lab samples will be conducted at 6 and 12 weeks.

Eligibility criteria: Inclusion Criteria:

* Previously molecularly confirmed NGLY1-CDDG
* Between the ages of 1 year old to 60 years old
* Parent or legal guardian available to provide consent on behalf of minor subjects or adult subjects who are unable to give informed consent due to developmental disabilities. Willingness of subject or legal guardian to provide consent.
* Non-pregnant, non-lactating female subjects of childbearing potential who are heterosexually active must agree to use a highly effective method of contraception for the duration of the study. A highly effective method of birth control is defined as one that results in a low failure rate (i.e., \&lt;1% per year) when used consistently and correctly, such as oral/injectable/inserted/implanted/transdermal contraceptives, condom with diaphragm, condom with spermicide, diaphragm with spermicide, intrauterine hormone- releasing system, or intrauterine device (IUD), or sexual abstinence. Contraception is not required where at least 6 weeks have passed since sterilization, defined as females having undergone one of the following surgeries: hysterectomy, bilateral tubal ligation or occlusion, bilateral oophorectomy, or bilateral salpingectomy; and males who are vasectomized. Contraception is not required where females are postmenopausal (defined as 12 consecutive months of spontaneous amenorrhea and age ≥51 years)..

Exclusion Criteria

* Hypersensitivity to any of the components of the placebo
* History of treatment with GlcNAc within 28 days of Visit 1
* Participation in another therapeutic trial - the subject will not be permitted to participate in any other drug trial during the blinded phase and during the 28 days prior to Visit 1
* Shellfish allergy
* Planned eye surgery within 3 months of enrollment
* • Females that are pregnant, nursing or less than 6 months postpartum or attempting to conceive

Primary outcomes:
measure: Difference in tear production from baseline in placebo vs GlcNAc group
timeFrame: 6 weeks
Secondary outcomes:
measure: Frequency of eye infections needing treatments
timeFrame: 6 weeks, 12 weeks
measure: Frequency of eye redness needing treatments
timeFrame: 6 weeks, 12 weeks
measure: Frequency of eye tearing/watering
timeFrame: 6 weeks, 12 weeks
measure: Frequency of light sensitivity
timeFrame: 6 weeks, 12 weeks
measure: Frequency of wind sensitivity
timeFrame: 6 weeks, 12 weeks
measure: Difference in tear production from baseline
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Children's Hospital of Philadelphia
state: Pennsylvania
city: Seattle
country: United States
facility: Seattle Children's Hospital
state: Washington
Study officials:
affiliation: Icahn School of Medicine at Mount Sinai
name: Eva Morava-Kozicz, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: